$1.78 pre RS. Sadly Johnson/Swartz/Pohl/King made a disastrous mistake by going it alone and we pay the price
Could not agree more. Would be good to know if this decision was due to low-ball offers or the company asking too much. With the right partner helping to fund multiple trials we would have stood a much better chance of finding out if PS targeting could be an important component in emerging IO therapies. They greedily bet the farm (at our expense) on the Ph3 trial.
News 
Market Data 
Discover 
